Search Within

Population Sciences Research Program

  1. "Lymphoma"
  2. "Adult Leukemia"
Formats
  1. Meeting Abstract (17)
  2. Journal Article (7)
  3. Book Section (1)
  4. Research Letter (1)
Groups
  1. Adult Leukemia (26)
  2. Center for Hematologic Malignancies (26)
  3. Department of Medicine (26)
  4. Hematologic Malignancies, Division of (26)
  5. Lymphoma (26)
  6. GSK Faculty (18)

More Groups

People
  1. Steven Horwitz (15)
  2. Ahmet Dogan (13)
  3. Maria Palomba (12)
  4. Andrew Zelenetz (10)
  5. Alison Moskowitz (9)
  6. Anas Younes (9)

More People

Years
  1. 2023 (5)
  2. 2021 (2)
  3. 2020 (4)
  4. 2019 (4)
  5. 2018 (3)
  6. 2015 (2)

More Years

Publications
  1. Blood (12)
  2. Journal of Clinical Oncology (4)
  3. Blood Advances (2)
  4. Laboratory Investigation (2)
  5. Biology of Blood and Marrow Transplantation (1)
  6. Blood Cancer Journal (1)

More Publications

Publishers
  1. American Society of Hematology (14)
  2. American Society of Clinical Oncology (4)
  3. Nature Publishing Group (4)
  4. American Association for Cancer Research (1)
  5. Elsevier Inc. (1)
  6. Elsevier Science, Inc. (1)

More Publishers

Results (26)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 2 study of minimal residual disease (MRD)-adapted front line venetoclax and obinutuzumab in fit patients with chronic lymphocytic leukemia (CLL): Effect of obinutuzumab on tumor lysis syndrome (TLS) risk and safety of outpatient venetoclax dose escalation
    Meeting Abstract

    Roeker, L. E.; Zelenetz, A. D.; Park, J. H.; Derkach, A.; Geyer, M. B.; Islam, P.; Falchi, L.; Palomba, M. L.; Kumar, A.; Salles, G.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A phase 1b multi-center study of the FLT3 inhibitor gilteritinib in combination with the IDH1 inhibitor ivosidenib or the IDH2 inhibitor enasidenib for patients with relapsed or refractory acute myeloid leukemia who have co-occurring FLT3/IDH1 or FLT3/IDH2 mutations
    Meeting Abstract

    Stein, E. M.; Derkach, A.; Melamed, G.; Block, A.; Kim, J.; Georgieva, G.; Thompson, V.; Levine, R. L.; Intlekofer, A. M.; Abdel-Wahab, O.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Pilot study of longitudinal geriatric assessment and neurocognitive evaluation in CAR T-cell therapy for older patients with relapsed refractory, large B-cell lymphoma
    Meeting Abstract

    Lin, R. J.; Kim, S. J.; Correa, D.; Elko, T. A.; Lobaugh, S.; Baser, R.; Koch, A.; Hanley, D. M.; Palomba, M. L.; Dahi, P. B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Ruxolitinib promotes clinical responses in large granular lymphocytic leukemia via suppression of JAK/STAT-dependent inflammatory cascades
    Meeting Abstract

    Moskowitz, A.; Rahman, J.; Ganesan, N.; Hannigan, K.; Ksanznak, K.; Bitton, H.; Lin, Y. H.; Davey, T.; Hancock, H.; Perez, L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Prospective geriatric assessment and geriatric consultation in CAR T-cell therapy for older patients with lymphoma
    Research Letter

    Lin, R. J.; Kim, S. J.; Brown, S.; Elko, T. A.; Ruiz, J. D.; Hanley, D. M.; Palomba, M. L.; Perales, M. A.; Shah, G. L.; Dahi, P. B.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas
    Journal Article

    Moskowitz, A. J.; Ghione, P.; Jacobsen, E.; Ruan, J.; Schatz, J. H.; Noor, S.; Myskowski, P.; Vardhana, S.; Ganesan, N.; Hancock, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Oncologic immunomodulatory agents in patients with cancer and COVID-19
    Journal Article

    Jee, J.; Stonestrom, A. J.; Devlin, S.; Nguyentran, T.; Wills, B.; Narendra, V.; Foote, M. B.; Lumish, M.; Vardhana, S. A.; Pastores, S. M.; more...
    Scientific Reports (2021)

    Fulltext@MSK | Save
  • Multispectral immunofluorescence identifies pS6 as a biomarker of intrinsic resistance to ruxolitinib in patients with relapsed/refractory T-cell lymphomas
    Meeting Abstract

    Ghione, P.; Moskowitz, A.; Kumar, P.; Knezevic, A.; Seshan, V.; Jacobsen, E.; Ruan, J.; Schatz, J.; Noor, S.; Myskowski, P.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Alternative anti-CD20 antibody versus desensitization for lymphoma patients with drug hypersensitivity reactions requiring discontinuation of rituximab, obinutuzumab, or ofatumumab
    Meeting Abstract

    Ghione, P.; Joffe, E.; De Paola, N.; Mainardi, T.; Noor, S. J.; Bobillo, S.; Myskowski, P. L.; Palomba, M. L.; Moskowitz, A. J.; Mato, A. R.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms
    Journal Article

    Lewis, N. E.; Petrova-Drus, K.; Huet, S.; Epstein-Peterson, Z. D.; Gao, Q.; Sigler, A. E.; Baik, J.; Ozkaya, N.; Moskowitz, A. J.; Kumar, A.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save